natgillin/translations-raw huggingface dataset:
Administration of Instanyl in single doses ranging from 50 to 200 micrograms fentanyl per dose in opioid tolerant cancer patients produces a rapid Cmax level of 0.35 to 1.2 ng/ml.
Primjenom jednostruke doze u rasponu od 50 do 200 mikrograma fentanila kod pacijenata s karcinomom koji podnose opioide brzo se postiže Cmax razina od 0,35 do 1,2 ng/ml.
Administration of insulin lispro to children below 12 years of age should be considered only in case of an expected benefit when compared to regular insulin.
Primjenu inzulina lispro u djece mlađe od 12 godina treba razmotriti samo ako se očekuje dodatna korist u odnosu na primjenu običnog inzulina.
administration of Invirase and parenteral midazolam.
Potreban je oprez pri istodobnoj primjeni lijeka Invirase i parenteralno primijenjenog midazolama.
Administration of iodinated contrast agent
Primjena jodnih kontrastnih sredstava
Administration of iodinated contrast agent
Primjena kontrastnih sredstava koja sadrže jod
Administration of iodinated contrast agent
Primjena kontrastnog sredstva koje sadrži jod
Administration of iodinated contrast agents
Primjena jodnih kontrastnih sredstava
Administration of Ipreziv for up to 5 days in subjects with mild (Child-Pugh A) or moderate (Child- Pugh B) hepatic impairment resulted in slight increase in azilsartan exposure (AUC increased by 1.3 to 1.6 fold, see section 4.2).
Primjena Ipreziva u trajanju do 5 dana u ispitanika s blagim (Child-Pugh A) ili umjerenim (Child- Pugh B) oštećenjem funkcije jetre dovela je do blagog povećanja izloženosti azilsartana (AUC povećan za 1,3 do 1,6 puta, vidjeti dio 4.2).
Administration of iron preparations and tetracyclines should be separated by 2 to 3 hours.
Pripravci željeza i tetraciklini trebaju se uzimati zasebno, uz dva ili tri sata vremenskog razmaka.
Administration of iron preparations with such compounds should be separated by at least 2 hours.
Pripravci željeza s takvim spojevima trebaju se uzimati zasebno, uz najmanje dva sata vremenskog razmaka.
Administration of isavuconazonium sulfate to rats at a dose of 90 mg/kg/day (2.3-fold the human maintenance dose [200 mg] based on mg/m2/day) during pregnancy through the weaning period showed an increased perinatal mortality of the pups.
Primjena izavukonazonijevog sulfata kod štakora u dozi od 90 mg/kg/dan (2,3 puta više od doze odrţavanja za čovjeka [200 mg] na temelju mg/m2/dan) tijekom graviditeta i razdoblja odvikavanja od sisanja pokazala je povećanu perinatalnu smrtnost mladunčadi.
Administration of IV parecoxib 40 mg had no significant effect on the pharmacokinetics of either IV fentanyl or IV alfentanil (CYP3A4 substrates).
Primjena i.v. parekoksiba u dozi od 40 mg nije imala značajnog učinka na farmakokinetiku niti i.v. fentanila niti i.v. alfentanila (supstrati CYP3A4).
Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP3A and/or P-gp, which may increase or prolong their therapeutic effect and adverse reactions.
Primjena ivakaftora može povećati sustavnu izloženost lijekovima koji su osjetljivi supstrati CYP3A i/ili P-gp, a to može povećati ili produljiti njihov terapijski učinak i nuspojave.
Administration of Kaletra with a high fat meal (872 kcal, 55.8% from fat) increased lopinavir AUC and Cmax by 96% and 43%, respectively, for soft capsules, and 130% and 56%, respectively, for oral solution.
Pri uzimanju lijeka Kaletra uz obrok s visokim sadržajem masti (872 kcal, 55,8% iz masnoća) AUC i Cmax lopinavira povećale su se, redom, za 96% i 43% pri uzimanju mekih kapsula, a za 130% i 56% pri uzimanju oralne otopine.
Administration of ketoconazole (400 mg for 18 days), a strong CYP3A4 inhibitor, with a single dose of regorafenib (160 mg on day 5) resulted in an increase in mean exposure (AUC) of regorafenib of approximately 33%, and a decrease in mean exposure of the active metabolites, M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), of approximately 90%.
Primjena ketokonazola (400 mg tijekom 18 dana), jakog inhibitora CYP3A4, i jedne doze regorafeniba (160 mg petog dana) rezultirala je povećanjem srednje vrijednosti izloženosti (AUC) regorafeniba za približno 33% i smanjenjem srednje vrijednosti izloženosti djelatnim metabolitima, M-2 (N-oksid) i M-5 (N-oksid i N-dezmetil) za približno 90%.
Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic medicinal products including ONIVYDE may result in serious or fatal infections; therefore vaccination with a live vaccine should be avoided.
Primjena živih ili živih atenuiranih cjepiva u bolesnika imunokompromitiranih kemoterapeuticima, uključujući ONIVYDE, mogla bi rezultirati ozbiljnim ili fatalnim infekcijama; stoga se cijepljenje živim cjepivima mora izbjegavati.
Administration of live vaccines (e.g.
Ne preporučuje se primjena živih cjepiva (npr.
Administration of live vaccines to infants exposed to abatacept in utero is not recommended for 14 weeks following the mother’s last exposure to abatacept during pregnancy.
Ne preporučuje se davati živa cjepiva novorođenčadi izloženoj abataceptu in utero tijekom 14 tjedana nakon majčina posljednjeg izlaganja abataceptu tijekom trudnoće.
Administration of live vaccines to infants exposed to adalimumab in utero is not recommended for 5 months following the mother’s last adalimumab injection during pregnancy.
Djeci koja su u maternici bila izložena adalimumabu ne preporučuje se davati živa cjepiva najmanje 5 mjeseci otkad je majka u trudnoći primila zadnju injekciju adalimumaba.
Administration of live vaccines to infants exposed to certolizumab pegol in utero is not recommended for a minimum of 5 months following the mother’s last Cimzia administration during pregnancy (see section 4.4).
Primjena živih cjepiva u novorođenčadi izloženih certolizumabpegolu in utero ne preporučuje se najmanje 5 mjeseci nakon posljednje primjene Cimzije kod majke tijekom trudnoće (vidjeti dio 4.4).
Administration of live vaccines to infants exposed to golimumab in utero is not recommended for 6 months following the mother’s last golimumab injection during pregnancy (see sections 4.4 and 4.5).
Ne preporučuje se primjena živih cjepiva u dojenčadi izloženoj golimumabu in utero u razdoblju od 6 mjeseci nakon posljednje injekcije golimumaba koju je majka primila tijekom trudnoće (vidjeti dijelove 4.4 i 4.5).
Administration of live vaccines to infants for 16 weeks after the mother’s last dose of Benepali is generally not recommended.
Primjena živih cjepiva dojenčadi 16 tjedana nakon majčine zadnje doze Benepalija obično se ne preporučuje.
Administration of live vaccines to infants for 16 weeks after the mother’s last dose of Enbrel is generally not recommended.
Primjena živih cjepiva dojenčadi 16 tjedana nakon majčine zadnje doze Enbrela obično se ne preporučuje.
Administration of Lymphoseek and conduct of the procedure
Primjena lijeka Lymphoseek i provođenje postupka
Administration of macitentan to female rats from late pregnancy through lactation at maternal exposures 5-fold the human exposure, caused reduced pup survival and impairment of the reproductive capability of the offspring, which was exposed to macitentan during late intrauterine life and via the milk during the suckling period.
Primjena macitentana na ženkama štakora od kasnog graviditeta do laktacije pri izloženosti majke 5 puta većoj od izloženosti kod ljudi uzrokovala je smanjeno preživljavanje mladunčadi i oštećenje sposobnosti razmnožavanja podmlatka izloženog macitentanu tijekom kasne faze boravka u maternici i putem mlijeka tijekom perioda sisanja.
Administration of Memantine Merz is not recommended in patients with severe hepatic impairment.
Ne preporučuje se primjena Memantine Merza kod bolesnika s teškim oštećenjem jetrene funkcije.
Administration of Memantine Mylan is not recommended in patients with severe hepatic impairment.
Ne preporučuje se primjena lijeka Memantine Mylan kod bolesnika s teškim oštećenjem jetre.
Administration of mifamurtide was commonly associated with transient neutropenia, usually when used in conjunction with chemotherapy.
Primjena mifamurtida bila je često povezana s prolaznom neutropenijom, obično kad se je koristio istovremeno s kemoterapijom.
Administration of miglustat to male and female Sprague-Dawley rats by oral gavage for 2 years at dose levels of 30, 60 and 180 mg/kg/day resulted in an increased incidence of testicular interstitial cell (Leydig cell) hyperplasia and adenomas in male rats at all dose levels.
Primjena miglustata kod muških i ženskih Sprague-Dawley štakora oralnom sondom tijekom 2 godine u dozama od 30, 60 i 180 mg/kg/dan za rezultat je imala povećanu incidenciju hiperplazije testikularnih intersticijskih stanica (Leydig cell) i adenome u muških štakora pri svim razinama doza.
Administration of Mimpara with food results in an approximate 50 – 80% increase in cinacalcet bioavailability.
Uzimanje Mimpare s hranom povećava bioraspoloživost sinakalceta za oko 50 do 80 %.
Administration of mirabegron at doses of 50 mg and 100 mg once daily for
Primjena mirabegrona u dozama od 50 mg i 100 mg jedanput na dan tijekom
Administration of multiple doses of tenofovir disoproxil fumarate with a meal to HIV infected patients resulted in mean (%CV) tenofovir Cmax, AUC, and Cmin values of 326 (36.6%) ng/ml, 3,324 (41.2%) ng·h/ml and
Davanje višestrukih doza tenofovirdizoproksilfumarata uz obrok u HIV-om zaraženih pacijenata rezultirala je srednjim (% koeficijenta varijacije) vrijednostima Cmax tenofovira od 326 (36,6%) ng/ml, AUC od
Administration of nintedanib was also associated with elevations of bilirubin.
Primjena nintedaniba također je bila povezana s povišenjem bilirubina.
Administration of nintedanib was associated with an elevation of liver enzymes (ALT, AST, ALKP, gamma-glutamyltransferase) or bilirubin, with a potentially higher risk for female patients.
Primjena nintedaniba je bila povezana s povišenjem vrijednosti jetrenih enzima (ALT, AST, AP, gama-glutamiltransferaze) ili bilirubina s potencijalno višim rizikom za bolesnice.
Administration of nintedanib was associated with elevations of liver enzymes (ALT, AST, alkaline phosphatase (ALKP), gamma-glutamyl-transferase (GGT)) with a potentially higher risk for female patients.
Primjena nintedaniba bila je povezana s povišenjem jetrenih enzima (ALT, AST, alkalne fosfataze (AP), gama-glutamil-transferaze (GGT)) uz potencijalno viši rizik za bolesnice.
Administration of Nucala to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
Primjenu lijeka Nucala u trudnica treba razmotriti samo ako je očekivana korist za majku veća od svih mogućih rizika za plod.
Administration of oral cyclosporine A (15 mg/kg), an inhibitor of transporters ABCB1 (P-gp) and ABCC1 (MRP-1) as well as the metabolising enzyme CYP3A4, within 4 hours of oral topotecan increased the dose normalised AUC0-24h of topotecan lactone and total topotecan approximately 2.0- and 2.5-fold, respectively (see section 4.5).
Primjena peroralnog ciklosporina A (15 mg/kg), inhibitora transportnih ABCB1 (P-gp) i ABCC1 (MRP-1), kao i metabolizirajućeg enzima CYP3A4, unutar 4 sata od oralnog topotekana povećala je dozu normalizirane AUC 0-24 h topotekan laktona približno 2,0 i ukupnog topotekana približno 2,5 puta, (vidjeti dio 4.5).
Administration of Orkambi may decrease systemic exposure of medicinal products which are substrates of CYP3A, thereby decreasing their therapeutic effect.
Primjena lijeka Orkambi može smanjiti sistemsku izloženost lijekovima koji su supstrati CYP3A, čime se smanjuje njihov terapijski učinak.
Administration of pain relievers into the joint is not recommended.
Ne preporučuje se primjena lijekova protiv bolova u zglob.
Administration of pazopanib with a high fat or low fat meal results in an approximately 2-fold increase in AUC and Cmax.
Primjena pazopaniba uz obrok sa puno ili malo masnoća rezultira s približno dvostrukim povećanjem vrijednosti AUC i Cmax.
Administration of pazopanib with a high fat or low fat meal results in an approximately 2-fold increase in AUC and Cmax.
Uzimanje pazopaniba s obrocima sa puno ili malo masti rezultiralo je s približno dvostrukim povećanjem AUC i Cmax.
Administration of pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures, and cleft palate
Primjena pemetrekseda u gravidnih ženki miševa rezultirala je smanjenjem preživljenja i tjelesne težine ploda, nepotpunim okoštavanjem nekih koštanih struktura i pojavom rascjepa nepca.
Administration of prednisolone may induce hypokalaemia and hence increase the risk of toxicity from cardiac glycosides.
Primjena prednizolona može inducirati hipokalemiju te stoga povećati rizik toksičnosti srčanih glikozida.
Administration of PREZISTA 800 mg once daily with low dose ritonavir in treatment-naïve adolescents 12 to 17 years weighing at least 40 kg leads to darunavir exposures within the therapeutic range as established in adults receiving the same dosing regimen.
Primjena lijeka PREZISTA od 800 mg jedanput na dan uz nisku dozu ritonavira u adolescenata u dobi od 12 do 17 godina težine najmanje 40 kg koji nisu prethodno liječeni, dovodi do izloženosti darunaviru unutar terapijskog raspona ustanovljenog u odraslih pri istom režimu doziranja.
Administration of protein-rich foods increases the bioavailability of propranolol by about 50% with no change in time to peak concentration.
Primjena hrane bogate proteinima povećava raspoloživost propranolola za oko 50% bez promjene vremena postizanja vršne koncentracije.
Administration of rapid-acting insulin is recommended in situations with severe hyperglycaemia.
U teškoj hiperglikemiji preporučuje se primjena brzodjelujućeg inzulina.
Administration of Remsima should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Ako bolesnik razvije novu ozbiljnu infekciju ili sepsu, treba prekinuti liječenje lijekom Remsima i uvesti odgovarajuću antimikrobnu ili antimikotičku terapiju sve dok infekcija ne bude pod kontrolom.
Administration of retigabine with a high fat meal resulted in no change in the overall extent of retigabine absorption, but food reduced the between-subject variability in Cmax (23%) compared to the fasted state (41%), and led to an increase in Cmax (38%).
Primjena retigabina uz obrok s velikom količinom masti nije rezultirala promjenama ukupne apsorpcije retigabina, ali je hrana umanjila varijabilnost Cmax (23%) u usporedbi s ispitanicima natašte (41%), i dovela do povećanja Cmax (38%).
Administration of rivastigmine oral solution with food delays absorption (tmax) by 74 min and lowers Cmax by 43% and increases AUC by approximately 9%.
Primjena oralne otopine s hranom odgađa apsorpciju (tmax) za 74 minuta te snižava Cmax za 43% i povećava AUC za otprilike 9%.
Administration of RoActemra should be interrupted if a patient develops a serious infection until the infection is controlled (see section 4.8).
Ako bolesnik razvije tešku infekciju, primjenu lijeka RoActemra treba privremeno prekinuti sve dok infekcija ne bude pod kontrolom (vidjeti dio 4.8).
Administration of Rotarix should be postponed in subjects suffering from acute severe febrile illness.
Primjena cjepiva Rotarix mora se odgoditi u osoba koje boluju od teže akutne bolesti praćene vrućicom.
Administration of Rotarix to infants who have known or suspected immunodeficiency should be based on careful consideration of potential benefits and risks.
Primjena cjepiva Rotarix u dojenčadi za koju se zna ili sumnja na imunodeficijenciju mora se temeljiti na pažljivom razmatranju mogućih koristi i rizika.
Administration of Rotarix to infants who have known or suspected immunodeficiency should be based on careful consideration of potential benefits and risks.
Primjenu cjepiva Rotarix u dojenčadi za koju se zna ili sumnja na imunodeficijenciju potrebno je temeljiti na pažljivom razmatranju mogućih koristi i rizika.
Administration of Scintimun and conduct of the procedure
Primjena Scintimuna i provođenje postupka
Administration of Simponi should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.
Liječenje lijekom Simponi treba prekinuti ukoliko bolesnik razvije novu ozbiljnu infekciju ili sepsu te treba uvesti odgovarajuću antimikrobnu ili antimikotičku terapiju sve dok infekcija ne bude pod kontrolom.
Administration of single subcutaneous dose 420 mg resulted in a Cmax mean (SD) of 46.0 (17.2) μg/mL and AUClast mean (SD) of 842 (333) day•μg/mL.
Primjena jednokratne supkutane doze od 420 mg rezultirala je srednjom vrijednosti Cmax (SD) od 46,0 (17,2) ng/ml i srednjom vrijednosti AUClast (SD) od 842 (333) dan•μg/ml.
Administration of sunitinib with potent CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John’s Wort/Hypericum perforatum) may decrease sunitinib concentrations.
Primjena sunitiniba sa snažnim induktorima CYP3A4 (npr. deksametazonom, fenitoinom, karbamazepinom, rifampicinom, fenobarbitalom ili biljnim lijekovima koji sadrže gospinu travu/Hypericum perforatum) može sniziti koncentracije sunitiniba.
Administration of sunitinib with potent CYP3A4 inhibitors (e.g. ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice) may increase sunitinib concentrations.
Primjena sunitiniba sa snažnim inhibitorima CYP3A4 (npr. ritonavirom, itrakonazolom, eritromicinom, klaritromicinom, sokom od grejpa) može povećati koncentracije sunitiniba.
Administration of Tasigna 30 minutes or hours after food increased bioavailability of nilotinib by 29% or 15%, respectively (see sections 4.2, 4.4 and 4.5).
Primjena Tasigne 30 minuta nakon hrane povećava bioraspoloživost nilotiniba za 29%, a 2 sata nakon hrane za 15% (vidjeti dijelove 4.2, 4.4 i 4.5).
Administration of tenofovir disoproxil fumarate with a high fat meal enhanced the oral bioavailability, with an increase in tenofovir AUC by approximately 40% and Cmax by approximately 14%.
Primjena tenofovirdizoproksilfumarata s obrokom bogatim mastima povećala je oralnu bioraspoloživost, kod čega se AUC vrijednost tenofovira povećala za približno 40%, a Cmax za približno 14%.
Administration of the CYP3A4 inhibitor ketoconazole with Akynzeo increased the AUC of netupitant fold and Cmax 1.3 fold when compared to the administration of Akynzeo alone.
Primjena ketokonazola, inhibitora CYP3A4, s Akynzeom povećala je AUC netupitanta 1,8 puta, a Cmax 1,3 puta u usporedbi s primjenom samog Akynzea.
Administration of the final diluted solution should be completed within six hours from the time that the Torisel is first added to sodium chloride 9 mg/ml (0.9%) solution for injection.
Primjenu otopine nakon konačnog razrjeđenja treba dovršiti u roku od šest sati od vremena kad se Torisel prvi put dodao u otopinu za injekciju natrijevog klorida od 9 mg/ml (0,9%).
Administration of the final diluted solution should be completed within six hours from the time that Torisel is first added to sodium chloride 9 mg/ml (0.9%) solution for injection.
Primjenu otopine nakon konačnog razrjeđenja treba dovršiti u roku od šest sati od vremena kad se Torisel prvo dodao u otopinu za injekciju natrijevog klorida od 9 mg/ml (0,9%).
Administration of the fosamprenavir oral suspension formulation with a high fat meal (967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) reduced plasma amprenavir AUC(0-) by 28% and Cmax by 46% and delayed Tmax by 0.72 hours.
Primjena fosamprenavira u obliku oralne suspenzije s obrokom koji ima visok udio masnoće (967 kcal, 67 grama masti, 33 grama proteina, 58 grama ugljikohidrata) smanjila je vrijednost AUC(0-) za amprenavir u plazmi za 28% i Cmax za 46% te je produljila Tmax za 0,72 sata.
Administration of the fosamprenavir tablet formulation in the fed state (standardised high fat meal: 967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) did not alter plasma amprenavir pharmacokinetics (Cmax, tmax or AUC0-) compared to the administration of this formulation in the fasted state.
Postprandijalna primjena fosamprenavira u obliku tableta (standardizirani obrok s visokim udjelom masnoća: 967 kcal, 67 g masti, 33 g proteina, 58 g ugljikohidrata) nije promijenila farmakokinetiku amprenavira u plazmi (Cmax, tmax ili AUC0-) u usporedbi s onom kod primjene ovog oblika lijeka natašte.
Administration of the infusion solution
Primjena otopine za infuziju
Administration of the medicine radiolabelled with EndolucinBeta and conduct of the procedure EndolucinBeta must be used only in combination with another medicine (carrier medicine) which has been specifically developed and authorised for being combined with Lutetium (177Lu) chloride.
Primjena lijeka koji je radioaktivno označen EndolucinBetom i provedba postupka EndolucinBeta smije se primjenjivati samo u kombinaciji s drugim lijekom (lijekom nosačem) koji je posebno razvijen i odobren za kombinaciju s lutecijevim (177Lu) kloridom.
Administration of the medicine radiolabelled with Lumark and conduct of the procedure
Primjena lijeka koji je radioaktivno označen Lumarkom i provođenje postupka
Administration of the oral contraceptive 1 hour or 4 hours after lixisenatide did not affect AUC and t1/2 of ethinylestradiol and levonorgestrel, whereas Cmax of ethinylestradiol was decreased by 52% and 39%respectively and Cmax of levonorgestrel was decreased by 46% and 20%, respectively and median tmax was delayed by 1 to 3 hours.
Primjena oralnog kontraceptiva 1 sat odnosno 4 sata nakon liksisenatida nije utjecala na AUC ni t1/2 etinilestradiola i levonorgestrela, ali je smanjila Cmax etinilestradiola za 52% odnosno 39% te Cmax levonorgestrela za 46% odnosno 20%, dok je medijan tmax bio odgođen za 1do 3 sata.
Administration of the oral contraceptive 35 minutes after exenatide did not affect AUC but resulted in a reduction of the Cmax of ethinyl estradiol by 45 %, and Cmax of levonorgestrel by 27-41 %, and a delay in tmax by 2-4 h due to delayed gastric emptying.
Primjena oralnog kontraceptiva 35 minuta nakon eksenatida nije utjecala na AUC, ali je rezultirala smanjenjem Cmax etinilestradiola za 45% i smanjenjem Cmax levonorgestrela za 27-41% te odgodom tmax za 2-4 sata zbog produljenog pražnjenja želuca.
Administration of the product at overdose (up to 5-fold of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN).
Primjena proizvoda u prekomjernoj dozi (do 5 puta većoj od preporučene tijekom 6 mjeseci) rezultirala je izrazitim sniženjem krvnog tlaka, smanjenjem broja crvenih krvnih stanica (učinci koji se mogu pripisati farmakološkoj aktivnosti proizvoda) i povećanjem urea nitrata u krvi (BUN).
Administration of the product at overdose (up to 5-fold of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN; nitrogen containing waste products in the blood).
Primjena proizvoda u prekomjernoj dozi (do 5 puta većoj od preporučene tijekom 6 mjeseci) rezultirala je izrazitim sniženjem krvnog tlaka, smanjenjem broja crvenih krvnih stanica (učinci koji se mogu pripisati farmakološkoj aktivnosti proizvoda) i povećanjem urea nitrata u krvi (BUN; otpadne tvari u krvi koje sadrže dušik).
Administration of the product by the subcutaneous route in cattle and the intramuscular route in pigs is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in cattle treated in clinical studies
Primjena proizvoda subkutanim putem u goveda i intramuskularnim putem u svinja dobro se podnosi; u goveda liječenih u kliničkim studijama uočeno je samo blago prolazno oticanje na mjestu ubrizgavanja, nakon subkutane primjene.
Administration of the reconstituted solution:
Primjena rekonstituirane otopine